|
| Publications [#79890] of Shelby Reed
Papers Published
- SD Reed, PW Dillingham, AH Briggs, DL Veenstra, SD Sullivan, A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results.,
Medical decision making : an international journal of the Society for Medical Decision Making, vol. 23 no. 3
(September, 2003),
pp. 252-64, ISSN 0272-989X
(last updated on 2013/07/01)
Abstract:
Pharmacy and therapeutics committees commonly cite a lack of generalizability as a reason for not incorporating cost-effectiveness information into decision making. To address this concern, many committees undertake site-specific economic evaluations, which are often limited by small sample sizes and nonrandomized designs. We show how 2 complementary approaches were used to minimize these limitations in an economic evaluation of abciximab at 1 institution. Using a propensity score methodology, we selected patients who did not receive abciximab for the comparison cohort. Then, we adopted a Bayesian, hierarchical, random-effects model to integrate site-specific and clinical trial data. We applied the posterior distributions of effectiveness with local cost data in a traditional decision-analytic model. In 74% of the simulations, abciximab was cost-effective at 1 institution at the $50,000 per life year saved threshold, assuming a 50:50 split of patients undergoing coronary stenting and angioplasty. Among patients undergoing coronary stenting, the cost-effectiveness ratio of the addition of abciximab was at or below the $50,000 per life year saved threshold in 66.0% of the simulations.
Keywords:
Angioplasty, Balloon, Coronary • Antibodies, Monoclonal* • Anticoagulants* • Bayes Theorem* • Coronary Artery Bypass • Coronary Disease* • Cost-Benefit Analysis* • Decision Making* • Female • Humans • Immunoglobulin Fab Fragments* • Male • Middle Aged • Randomized Controlled Trials as Topic • drug therapy • economics • economics* • methods • therapeutic use • therapy
|
